These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 36918740)
1. Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials. Pericàs JM; Di Prospero NA; Anstee QM; Mesenbrinck P; Kjaer MS; Rivera-Esteban J; Koenig F; Sena E; Pais R; Manzano R; Genescà J; Tacke F; Ratziu V; Aliment Pharmacol Ther; 2023 May; 57(9):948-961. PubMed ID: 36918740 [TBL] [Abstract][Full Text] [Related]
2. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. Pericàs JM; Tacke F; Anstee QM; Di Prospero NA; Kjær MS; Mesenbrink P; Koenig F; Genescà J; Ratziu V; J Hepatol; 2023 Feb; 78(2):442-447. PubMed ID: 36216134 [TBL] [Abstract][Full Text] [Related]
3. Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints. Meyer EL; Mesenbrink P; Di Prospero NA; Pericàs JM; Glimm E; Ratziu V; Sena E; König F; PLoS One; 2023; 18(3):e0281674. PubMed ID: 36893087 [TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Aggarwal P; Noureddin M; Harrison S; Jeannin S; Alkhouri N Expert Opin Investig Drugs; 2022 Feb; 31(2):163-172. PubMed ID: 35060815 [TBL] [Abstract][Full Text] [Related]
6. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Fraile JM; Palliyil S; Barelle C; Porter AJ; Kovaleva M Drug Des Devel Ther; 2021; 15():3997-4009. PubMed ID: 34588764 [TBL] [Abstract][Full Text] [Related]
7. Multi-drug approaches to NASH: what's in the development pipeline? Johnston MP; Patel J; Byrne CD Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533 [No Abstract] [Full Text] [Related]
8. Promising therapies for treatment of nonalcoholic steatohepatitis. Noureddin M; Zhang A; Loomba R Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374 [TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980 [TBL] [Abstract][Full Text] [Related]
11. NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Harvey BE Acta Pharmacol Sin; 2022 May; 43(5):1210-1214. PubMed ID: 35110697 [TBL] [Abstract][Full Text] [Related]
12. Regulatory Issues of Platform Trials: Learnings from EU-PEARL. Nguyen QL; Hees K; Hernandez Penna S; König F; Posch M; Bofill Roig M; Meyer EL; Freitag MM; Parke T; Otte M; Dauben HP; Mielke T; Spiertz C; Mesenbrink P; Gidh-Jain M; Pierre S; Morello S; Hofner B Clin Pharmacol Ther; 2024 Jul; 116(1):52-63. PubMed ID: 38529786 [TBL] [Abstract][Full Text] [Related]
13. The future R&D landscape in non-alcoholic steatohepatitis (NASH). Black D; Brockbank S; Cruwys S; Goldenstein K; Hein P; Humphries B Drug Discov Today; 2019 Feb; 24(2):560-566. PubMed ID: 30291900 [TBL] [Abstract][Full Text] [Related]
15. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793 [TBL] [Abstract][Full Text] [Related]
16. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Drenth JPH; Schattenberg JM Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Ng CH; Muthiah MD; Xiao J; Chin YH; Lim G; Lim WH; Tay P; Tan DJH; Yong JN; Pan XH; Koh JWH; Chew N; Syn N; Tan E; Huang DQ; Siddiqui MS; Loomba R; Sanyal AJ; Noureddin M Aliment Pharmacol Ther; 2022 May; 55(9):1076-1087. PubMed ID: 35285529 [TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Cusi K Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]